Cipla celebrates 90 years with focus on quality products, global presence, and investment in research and technology.

Our Cipla Health franchise grew by 16% with margins reaching closer to mid-teens for the quarter. Big brands of Cipla Health scaled further by posting double-digit growth in revenues,” it stated.

MUMBAI (Reuters) - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a ...

Cipla Enters the Respiratory Market in Germany and Sweden with Affordable High Quality Alternatives. By Carly Helfand Sep 2, 2014 10:29am. MUMBAI, Sep 01, 2014 (PR Newswire Europe via ...

Cipla , India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of its respiratory and cancer drugs in its key ...

Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief ...

Cipla's complex respiratory portfolio drives profitability, according to Sharekhan Anticipated rise in EBITDA margins to 26% by FY26E Stock trading at a revised PT of Rs. 1,700, up from Rs. 1,600 ...

NEW YORK, May 27, 2025 /PRNewswire/ -- Cipla USA Inc. (Cipla USA) announced its continued collaboration with the American Lung Association for the 11th annual LUNG FORCE Walk, reaffirming its ...